MODIA is a 6-month digital mental health program designed to help patients with OUD develop behavioral coping skills. MODIA incorporates various supportive techniques like cognitive behavioral therapy (CBT) and motivational interviewing. MODIA is intended for use by patients who are engaged in a clinician-directed Medication-Assisted Treatment (MAT) plan for OUD.
Opioid use disorder
Being addictive to drugs is a chronic disease that affects both a person’s brain and their behavior resulting in a significant impact on their quality of life. Treatment of opioid use disorder (OUD) is often administered over long periods of time or chronically.
The most common treatments are Medication Assisted Treatments (MAT) based on buprenorphine, methadone or naltrexone. Buprenorphine is often combined with the antagonist naloxone to help prevent misuse by intravenous injection. The most frequently used medication as part of a MAT program in the US is buprenorphine/naloxone which can be taken under the tongue as a tablet or film. Methadone is most commonly administered orally in a supervised setting, while naltrexone is most frequently given as a monthly injection.
Pharmacological treatment should be provided as part of a complete treatment plan and include behavioral therapy.
People where misuse of opioids has turned to illicit drug use face a large risk of suffering life-threatening overdoses where rescue medications such as naloxone are often required.
MODIA®: Digital mental health program for OUD
Products under development: Overdose rescue medications
IZIPRY™ (former OX124) is a late-stage, high dose nasal powder with naloxone to be used in life-threatening situations where the overdose on any opioid is suspected, indicated by e.g. unconsciousness or opioid-induce respiratory depression (OIRD). Izipry is developed based on the AmorphOX® technology.
OX390 is a New Chemical Entity (NCE) with a novel formulation and route of administration, supported by the AmorphOX technology. It is intended to reverse respiratory depression from adulterated overdoses. Orexo is developing, OX390, in partnership with BARDA.1
OX125 is an early-stage powder-based formulation of nalmefene for intranasal administration in life-threatening situations where the overdose on any opioid is suspected. Nalmefene has a prolonged half-life compared to naloxone and may potentially last longer than the majority of highly potent synthetic opioids. OX125 is developed based on the AmorphOX technology.
1 Biomedical Advanced Research and Development Authority
